Ye et al. demonstrated that dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, exerts cardioprotection in type 2 diabetic mice by attenuating the protein levels of NALP3, ASC, IL-1β, IL-6, and caspase-1 in mouse hearts, thereby inhibiting the activation of the NLRP3 inflammasome (83). This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.